Nuclear receptors and nonalcoholic fatty liver disease

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1859, Issue 9, 2016, Pages 1083-1099

  Cave, Matthew C ^a,b,c   Clair, Heather B ^a   Hardesty, Josiah E ^a   Falkner, K Cameron ^a   Feng, Wenke ^a   Clark, Barbara J ^a   Sidey, Jennifer ^a   Shi, Hongxue ^a   Aqel, Bashar A ^d   McClain, Craig J ^a,b,c   Prough, Russell A ^a  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c JEWISH HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

CAR; FXR; LXR; NAFLD; NASH; PCBs; PPAR; PXR; TAFLD; TASH

Indexed keywords

CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; NEW DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; STEROID RECEPTOR; XENOBIOTIC AGENT;

ARTICLE; CHEMOTHERAPY ASSOCIATED STEATOHEPATITIS; DYSLIPIDEMIA; FATTY LIVER; HEPATITIS; HUMAN; INSULIN RESISTANCE; LIVER CANCER; LIVER FIBROSIS; LIVER METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; TOXICANT ASSOCIATED STEATOHEPATITIS; ADIPOSE TISSUE; AGONISTS; ANIMAL; DRUG EFFECTS; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; DRUGS, INVESTIGATIONAL; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HUMANS; LIVER; LIVER X RECEPTORS; NON-ALCOHOLIC FATTY LIVER DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTOR CROSS-TALK; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; SIGNAL TRANSDUCTION; XENOBIOTICS;

EID: 84962592586     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2016.03.002     Document Type: Article

References (251)

1. [1] Joshi-Barve, S., Kirpich, I., Cave, M.C., Marsano, L., McClain, C.J., Alcoholic, non-alcoholic and toxicant-associated steatohepatitis: mechanistic similarities and differences. Cell. Mol. Gastroenterol. Hepatol., 1 (2015), 356–367.
2. [2] Wahlang, B., Beier, J.I., Clair, H.B., Bellis-Jones, H.J., Falkner, K.C., McClain, C.J., Cave, M.C., Toxicant-associated steatohepatitis. Toxicol. Pathol. 41 (2013), 343–360.
3. [3] Ludwig, J., Viggiano, T.R., McGill, D.B., Oh, B.J., Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55 (1980), 434–438.
4. [4] Anderson, E.L., Howe, L.D., Jones, H.E., Higgins, J.P., Lawlor, D.A., Fraser, A., The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One, 10, 2015, e0140908.
5. [5] Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology, 2015.
6. [6] James, O.F., Day, C.P., Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J. Hepatol. 29 (1998), 495–501.
7. [7] Ducheix, S., Montagner, A., Theodorou, V., Ferrier, L., Guillou, H., The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease. Biochem. Pharmacol. 86 (2013), 96–105.
8. [8] Lopez-Velazquez, J.A., Carrillo-Cordova, L.D., Chavez-Tapia, N.C., Uribe, M., Mendez-Sanchez, N., Nuclear receptors in nonalcoholic fatty liver disease. J. Lipid, 2012, 2012, 139875.
9. [9] Xu, J.Y., Li, Z.P., Zhang, L., Ji, G., Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. World J. Gastroenterol. 20 (2014), 13493–13500.
10. [10] Evans, R.M., Mangelsdorf, D.J., Nuclear receptors, RXR, and the big bang. Cell 157 (2014), 255–266.
11. [11] Willett, C., Caverly Rae, J., Goyak, K.O., Landesmann, B., Minsavage, G., Westmoreland, C., Pathway-based toxicity: history, current approaches and liver fibrosis and steatosis as prototypes. ALTEX 31 (2014), 407–421.
12. [12] Mellor, C.L., Steinmetz, F.P., Cronin, M.T., The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. Crit. Rev. Toxicol., 2015, 1–15.
13. [13] Ding, N., Yu, R.T., Subramaniam, N., Sherman, M.H., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., Lau, S.L., Atkins, A.R., Barish, G.D., Gunton, J.E., Liddle, C., Downes, M., Evans, R.M., A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153 (2013), 601–613.
14. [14] Kojetin, D.J., Burris, T.P., REV-ERB and ROR nuclear receptors as drug targets. Nat. Rev. Drug Discov. 13 (2014), 197–216.
15. [15] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Chalasani, N., Dasarathy, S., Diehl, A.M., Hameed, B., Kowdley, K.V., McCullough, A., Terrault, N., Clark, J.M., Tonascia, J., Brunt, E.M., Kleiner, D.E., Doo, E., for the N.C.R.N., Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
16. [16] Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., Lavine, J.E., Tonascia, J., Unalp, A., Van Natta, M., Clark, J., Brunt, E.M., Kleiner, D.E., Hoofnagle, J.H., Robuck, P.R., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362 (2010), 1675–1685.
17. [17] Issemann, I., Green, S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990), 645–650.
18. [18] Patsouris, D., Reddy, J.K., Muller, M., Kersten, S., Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147 (2006), 1508–1516.
19. [19] Tailleux, A., Wouters, K., Staels, B., Roles of PPARs in NAFLD: potential therapeutic targets. Biochim. Biophys. Acta 1821 (2012), 809–818.
20. [20] Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.R., Van Hul, W., Mertens, I., Hubens, G., Van Marck, E., Michielsen, P., Van Gaal, L., Staels, B., PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J. Hepatol., 2015.
21. [21] Zhao, W., Liu, L., Wang, Y., Mao, T., Li, J., Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-gamma and insulin receptor in a rat model of nonalcoholic fatty liver disease. Exp. Ther. Med. 11 (2016), 183–190.
22. [22] Yu, K., Bayona, W., Kallen, C.B., Harding, H.P., Ravera, C.P., McMahon, G., Brown, M., Lazar, M.A., Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270 (1995), 23975–23983.
23. [23] Narala, V.R., Adapala, R.K., Suresh, M.V., Brock, T.G., Peters-Golden, M., Reddy, R.C., Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J. Biol. Chem. 285 (2010), 22067–22074.
24. [24] Reddy, J.K., Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001), G1333–G1339.
25. [25] Tanaka, N., Takahashi, S., Zhang, Y., Krausz, K.W., Smith, P.B., Patterson, A.D., Gonzalez, F.J., Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. Biochim. Biophys. Acta 1852 (2015), 1242–1252.
26. [26] Takeuchi, S., Matsuda, T., Kobayashi, S., Takahashi, T., Kojima, H., In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway. Toxicol. Appl. Pharmacol. 217 (2006), 235–244.
27. [27] Corton, J.C., Cunningham, M.L., Hummer, B.T., Lau, C., Meek, B., Peters, J.M., Popp, J.A., Rhomberg, L., Seed, J., Klaunig, J.E., Mode of action framework analysis for receptor-mediated toxicity: the peroxisome proliferator-activated receptor alpha (PPARalpha) as a case study. Crit. Rev. Toxicol. 44 (2014), 1–49.
28. [28] Laughter, A.R., Dunn, C.S., Swanson, C.L., Howroyd, P., Cattley, R.C., Corton, J.C., Role of the peroxisome proliferator-activated receptor alpha (PPARalpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology 203 (2004), 83–98.
29. [29] Corton, J.C., Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARalpha) in mouse liver tumor induction by trichloroethylene and metabolites. Crit. Rev. Toxicol. 38 (2008), 857–875.
30. [30] Zhu, Y., Alvares, K., Huang, Q., Rao, M.S., Reddy, J.K., Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. 268 (1993), 26817–26820.
31. [31] Stienstra, R., Duval, C., Muller, M., Kersten, S., PPARs, obesity, and inflammation. PPAR Res., 2007, 2007, 95974.
32. [32] Buechler, C., Wanninger, J., Neumeier, M., Adiponectin, a key adipokine in obesity related liver diseases. World J. Gastroenterol. 17 (2011), 2801–2811.
33. [33] Janesick, A., Blumberg, B., Minireview: PPARgamma as the target of obesogens. J. Steroid Biochem. Mol. Biol. 127 (2011), 4–8.
34. [34] Fisher, C.D., Jackson, J.P., Lickteig, A.J., Augustine, L.M., Cherrington, N.J., Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch. Toxicol. 82 (2008), 959–964.
35. [35] Gaudel, C., Grimaldi, P.A., Metabolic functions of peroxisome proliferator-activated receptor beta/delta in skeletal muscle. PPAR Res., 2007, 2007, 86394.
36. [36] Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R.X., Tachibana, K., Watanabe, Y., Uchiyama, Y., Sumi, K., Iguchi, H., Ito, S., Doi, T., Hamakubo, T., Naito, M., Auwerx, J., Yanagisawa, M., Kodama, T., Sakai, J., Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 15924–15929.
37. [37] Sznaidman, M.L., Haffner, C.D., Maloney, P.R., Fivush, A., Chao, E., Goreham, D., Sierra, M.L., LeGrumelec, C., Xu, H.E., Montana, V.G., Lambert, M.H., Willson, T.M., Oliver, W.R. Jr., Sternbach, D.D., Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)—synthesis and biological activity. Bioorg. Med. Chem. Lett. 13 (2003), 1517–1521.
38. [38] Peters, J.M., Aoyama, T., Burns, A.M., Gonzalez, F.J., Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim. Biophys. Acta 1632 (2003), 80–89.
39. [39] Wu, H.Q., Masset-Brown, J., Tweedie, D.J., Milewich, L., Frenkel, R.A., Martin-Wixtrom, C., Estabrook, R.W., Prough, R.A., Induction of microsomal NADPH-cytochrome P-450 reductase and cytochrome P-450IVA1 (P-450LA omega) by dehydroepiandrosterone in rats: a possible peroxisomal proliferator. Cancer Res. 49 (1989), 2337–2343.
40. [40] Yu, S., Matsusue, K., Kashireddy, P., Cao, W.Q., Yeldandi, V., Yeldandi, A.V., Rao, M.S., Gonzalez, F.J., Reddy, J.K., Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 278 (2003), 498–505.
41. [41] Lee, J.Y., Hashizaki, H., Goto, T., Sakamoto, T., Takahashi, N., Kawada, T., Activation of peroxisome proliferator-activated receptor-alpha enhances fatty acid oxidation in human adipocytes. Biochem. Biophys. Res. Commun. 407 (2011), 818–822.
42. [42] Goto, T., Lee, J.Y., Teraminami, A., Kim, Y.I., Hirai, S., Uemura, T., Inoue, H., Takahashi, N., Kawada, T., Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. J. Lipid Res. 52 (2011), 873–884.
43. [43] Reddy, J.K., Rao, M.S., Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006), G852–G858.
44. [44] Ip, E., Farrell, G., Hall, P., Robertson, G., Leclercq, I., Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39 (2004), 1286–1296.
45. [45] Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., Kooistra, T., Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J. Biol. Chem. 279 (2004), 16154–16160.
46. [46] Lalloyer, F., Wouters, K., Baron, M., Caron, S., Vallez, E., Vanhoutte, J., Bauge, E., Shiri-Sverdlov, R., Hofker, M., Staels, B., Tailleux, A., Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 1573–1579.
47. [47] Shan, W., Nicol, C.J., Ito, S., Bility, M.T., Kennett, M.J., Ward, J.M., Gonzalez, F.J., Peters, J.M., Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 47 (2008), 225–235.
48. [48] Shan, W., Palkar, P.S., Murray, I.A., McDevitt, E.I., Kennett, M.J., Kang, B.H., Isom, H.C., Perdew, G.H., Gonzalez, F.J., Peters, J.M., Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol. Sci. 105 (2008), 418–428.
49. [49] Kawaguchi, K., Sakaida, I., Tsuchiya, M., Omori, K., Takami, T., Okita, K., Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem. Biophys. Res. Commun. 315 (2004), 187–195.
50. [50] Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., Shibata, N., Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 536 (2006), 182–191.
51. [51] Fernandez-Miranda, C., Perez-Carreras, M., Colina, F., Lopez-Alonso, G., Vargas, C., Solis-Herruzo, J.A., A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig. Liver Dis. 40 (2008), 200–205.
52. [52] Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L.J., Baron, M., Lucas, A., Tailleux, A., Hum, D.W., Ratziu, V., Cariou, B., Hanf, R., Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58 (2013), 1941–1952.
53. [53] Cariou, B., Hanf, R., Lambert-Porcheron, S., Zair, Y., Sauvinet, V., Noel, B., Flet, L., Vidal, H., Staels, B., Laville, M., Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 36 (2013), 2923–2930.
54. [54] Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J.M., Gonzalez, F.J., Fruchart, J.C., Tedgui, A., Haegeman, G., Staels, B., Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274 (1999), 32048–32054.
55. [55] Delerive, P., Fruchart, J.C., Staels, B., Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169 (2001), 453–459.
56. [56] Delerive, P., De Bosscher, K., Vanden Berghe, W., Fruchart, J.C., Haegeman, G., Staels, B., DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol. Endocrinol. 16 (2002), 1029–1039.
57. [57] Delerive, P., Gervois, P., Fruchart, J.C., Staels, B., Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275 (2000), 36703–36707.
58. [58] Wahli, W., Michalik, L., PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol. Metab. 23 (2012), 351–363.
59. [59] van der Meer, D.L., Degenhardt, T., Vaisanen, S., de Groot, P.J., Heinaniemi, M., de Vries, S.C., Muller, M., Carlberg, C., Kersten, S., Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis. Nucleic Acids Res. 38 (2010), 2839–2850.
60. [60] Wu, Z., Rosen, E.D., Brun, R., Hauser, S., Adelmant, G., Troy, A.E., McKeon, C., Darlington, G.J., Spiegelman, B.M., Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell 3 (1999), 151–158.
61. [61] Lutchman, G., Modi, A., Kleiner, D.E., Promrat, K., Heller, T., Ghany, M., Borg, B., Loomba, R., Liang, T.J., Premkumar, A., Hoofnagle, J.H., The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46 (2007), 424–429.
62. [62] Furukawa, K., Numoto, S., Furuya, K., Furukawa, N.T., Williams, G.M., Effects of the hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital. Cancer Res. 45 (1985), 5011–5019.
63. [63] Shah, Y.M., Morimura, K., Yang, Q., Tanabe, T., Takagi, M., Gonzalez, F.J., Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol. Cell. Biol. 27 (2007), 4238–4247.
64. [64] Gonzalez, F.J., Shah, Y.M., PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246 (2008), 2–8.
65. [65] Palmer, C.N., Hsu, M.H., Griffin, K.J., Raucy, J.L., Johnson, E.F., Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 53 (1998), 14–22.
66. [66] Zhang, J., Kuehl, P., Green, E.D., Touchman, J.W., Watkins, P.B., Daly, A., Hall, S.D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Wrighton, S.A., Hancock, M., Kim, R.B., Strom, S., Thummel, K., Russell, C.G., Hudson, J.R. Jr., Schuetz, E.G., Boguski, M.S., The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11 (2001), 555–572.
67. [67] Lamba, V., Yasuda, K., Lamba, J.K., Assem, M., Davila, J., Strom, S., Schuetz, E.G., PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol. Appl. Pharmacol. 199 (2004), 251–265.
68. [68] Wright, M.C., The impact of pregnane X receptor activation on liver fibrosis. Biochem. Soc. Trans. 34 (2006), 1119–1123.
69. [69] Haughton, E.L., Tucker, S.J., Marek, C.J., Durward, E., Leel, V., Bascal, Z., Monaghan, T., Koruth, M., Collie-Duguid, E., Mann, D.A., Trim, J.E., Wright, M.C., Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 131 (2006), 194–209.
70. [70] Sookoian, S., Castano, G.O., Burgueno, A.L., Gianotti, T.F., Rosselli, M.S., Pirola, C.J., The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 20 (2010), 1–8.
71. [71] Breuker, C., Planque, C., Rajabi, F., Nault, J.C., Couchy, G., Zucman-Rossi, J., Evrard, A., Kantar, J., Chevet, E., Bioulac-Sage, P., Ramos, J., Assenat, E., Joubert, D., Pannequin, J., Hollande, F., Pascussi, J.M., Characterization of a novel PXR isoform with potential dominant-negative properties. J. Hepatol. 61 (2014), 609–616.
72. [72] Willson, T.M., Kliewer, S.A., PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1 (2002), 259–266.
73. [73] Tolson, A.H., Wang, H., Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv. Drug Deliv. Rev. 62 (2010), 1238–1249.
74. [74] Goodwin, B., Hodgson, E., Liddle, C., The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56 (1999), 1329–1339.
75. [75] Fromm, M.F., Kauffmann, H.M., Fritz, P., Burk, O., Kroemer, H.K., Warzok, R.W., Eichelbaum, M., Siegmund, W., Schrenk, D., The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol. 157 (2000), 1575–1580.
76. [76] Zhou, J., Zhai, Y., Mu, Y., Gong, H., Uppal, H., Toma, D., Ren, S., Evans, R.M., Xie, W., A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281 (2006), 15013–15020.
77. [77] Maglich, J.M., Stoltz, C.M., Goodwin, B., Hawkins-Brown, D., Moore, J.T., Kliewer, S.A., Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 62 (2002), 638–646.
78. [78] Falkner, K.C., Pinaire, J.A., Xiao, G.H., Geoghegan, T.E., Prough, R.A., Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol. Pharmacol. 60 (2001), 611–619.
79. [79] Bitter, A., Rummele, P., Klein, K., Kandel, B.A., Rieger, J.K., Nussler, A.K., Zanger, U.M., Trauner, M., Schwab, M., Burk, O., Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. arch. toxicol. 89 (2014), 2089–2103.
80. [80] He, J., Gao, J., Xu, M., Ren, S., Stefanovic-Racic, M., O'Doherty, R.M., Xie, W., PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes 62 (2013), 1876–1887.
81. [81] Spruiell, K., Richardson, R.M., Cullen, J.M., Awumey, E.M., Gonzalez, F.J., Gyamfi, M.A., Role of pregnane X receptor in obesity and glucose homeostasis in male mice. J. Biol. Chem. 289 (2014), 3244–3261.
82. [82] Watkins, R.E., Wisely, G.B., Moore, L.B., Collins, J.L., Lambert, M.H., Williams, S.P., Willson, T.M., Kliewer, S.A., Redinbo, M.R., The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292 (2001), 2329–2333.
83. [83] Al-Salman, F., Plant, N., Non-coplanar polychlorinated biphenyls (PCBs) are direct agonists for the human pregnane-X receptor and constitutive androstane receptor, and activate target gene expression in a tissue-specific manner. Toxicol. Appl. Pharmacol. 263 (2012), 7–13.
84. [84] Wahlang, B., Falkner, K.C., Clair, H.B., Al-Eryani, L., Prough, R.A., States, J.C., Coslo, D.M., Omiecinski, C.J., Cave, M.C., Human receptor activation by aroclor 1260, a polychlorinated biphenyl mixture. Toxicol. Sci. 140 (2014), 283–297.
85. [85] Krasowski, M.D., Ni, A., Hagey, L.R., Ekins, S., Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol. Cell. Endocrinol. 334 (2011), 39–48.
86. [86] Cheng, Y., Redinbo, M.R., Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721. Protein Sci. 20 (2011), 1713–1719.
87. [87] Kliewer, S.A., Goodwin, B., Willson, T.M., The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23 (2002), 687–702.
88. [88] Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., Lee, J.H., Khadem, S., Ren, S., Li, S., Silverstein, R.L., Xie, W., Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134 (2008), 556–567.
89. [89] Wada, T., Gao, J., Xie, W., PXR and CAR in energy metabolism. Trends Endocrinol. Metab. 20 (2009), 273–279.
90. [90] Li, L., Li, H., Garzel, B., Yang, H., Sueyoshi, T., Li, Q., Shu, Y., Zhang, J., Hu, B., Heyward, S., Moeller, T., Xie, W., Negishi, M., Wang, H., SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver. Mol. Pharmacol. 87 (2015), 674–682.
91. [91] Nakamura, K., Moore, R., Negishi, M., Sueyoshi, T., Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J. Biol. Chem. 282 (2007), 9768–9776.
92. [92] Bhalla, S., Ozalp, C., Fang, S., Xiang, L., Kemper, J.K., Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279 (2004), 45139–45147.
93. [93] Biswas, A., Pasquel, D., Tyagi, R.K., Mani, S., Acetylation of pregnane X receptor protein determines selective function independent of ligand activation. Biochem. Biophys. Res. Commun. 406 (2011), 371–376.
94. [94] Xie, W., Barwick, J.L., Downes, M., Blumberg, B., Simon, C.M., Nelson, M.C., Neuschwander-Tetri, B.A., Brunt, E.M., Guzelian, P.S., Evans, R.M., Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406 (2000), 435–439.
95. [95] Spruiell, K., Jones, D.Z., Cullen, J.M., Awumey, E.M., Gonzalez, F.J., Gyamfi, M.A., Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice. Biochem. Pharmacol. 89 (2014), 399–412.
96. [96] Rysa, J., Buler, M., Savolainen, M.J., Ruskoaho, H., Hakkola, J., Hukkanen, J., Pregnane X receptor agonists impair postprandial glucose tolerance. Clin. Pharmacol. Ther. 93 (2013), 556–563.
97. [97] Venkatesh, M., Mukherjee, S., Wang, H., Li, H., Sun, K., Benechet, A.P., Qiu, Z., Maher, L., Redinbo, M.R., Phillips, R.S., Fleet, J.C., Kortagere, S., Mukherjee, P., Fasano, A., Le Ven, J., Nicholson, J.K., Dumas, M.E., Khanna, K.M., Mani, S., Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 41 (2014), 296–310.
98. [98] Sun, M., Cui, W., Woody, S.K., Staudinger, J.L., Pregnane X receptor modulates the inflammatory response in primary cultures of hepatocytes. Drug Metab. Dispos. 43 (2015), 335–343.
99. [99] Wistuba, W., Gnewuch, C., Liebisch, G., Schmitz, G., Langmann, T., Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J. Gastroenterol. 13 (2007), 4230–4235.
100. [100] Niu, Y., Wu, Z., Shen, Q., Song, J., Luo, Q., You, H., Shi, G., Qin, W., Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. Dig. Liver Dis. 45 (2013), 1041–1048.
101. [101] Auerbach, S.S., Ramsden, R., Alternatively Spliced Isoforms of the Human Constitutive Androstane Receptor. 31, 2003, 3194–3207.
102. [102] Arnold, K.A., Eichelbaum, M., Burk, O., Alternative splicing affects the function and tissue-specific expression of the human constitutive androstane receptor. Nucl. Recept., 2, 2004, 1.
103. [103] Nishimura, M., Naito, S., Yokoi, T., Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab. Pharmacokinet. 19 (2004), 135–149.
104. [104] Zhang, Y.K., Lu, H., Klaassen, C.D., Expression of human CAR splicing variants in BAC-transgenic mice. Toxicol. Sci. 132 (2013), 142–150.
105. [105] DeKeyser, J.G., Stagliano, M.C., Auerbach, S.S., Prabhu, K.S., Jones, A.D., Omiecinski, C.J., Di(2-ethylhexyl) phthalate is a highly potent agonist for the human constitutive androstane receptor splice variant CAR2. Mol. Pharmacol. 75 (2009), 1005–1013.
106. [106] Lau, A.J., Chang, T.K., Indirect activation of the SV23 and SV24 splice variants of human constitutive androstane receptor: analysis with 3-hydroxyflavone and its analogues. Br. J. Pharmacol. 170 (2013), 403–414.
107. [107] Lau, A.J., Yang, G., Chang, T.K., Isoform-selective activation of human constitutive androstane receptor by Ginkgo biloba extract: functional analysis of the SV23, SV24, and SV25 splice variants. J. Pharmacol. Exp. Ther. 339 (2011), 704–715.
108. [108] Beilke, L.D., Aleksunes, L.M., Holland, R.D., Besselsen, D.G., Beger, R.D., Klaassen, C.D., Cherrington, N.J., Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab. Dispos. 37 (2009), 1035–1045.
109. [109] Uppal, H., Toma, D., Saini, S.P., Ren, S., Jones, T.J., Xie, W., Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41 (2005), 168–176.
110. [110] Gachon, F., Olela, F.F., Schaad, O., Descombes, P., Schibler, U., The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4 (2006), 25–36.
111. [111] Cerveny, L., Svecova, L., Anzenbacherova, E., Vrzal, R., Staud, F., Dvorak, Z., Ulrichova, J., Anzenbacher, P., Pavek, P., Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos. 35 (2007), 1032–1041.
112. [112] Faucette, S.R., Wang, H., Hamilton, G.A., Jolley, S.L., Gilbert, D., Lindley, C., Yan, B., Negishi, M., LeCluyse, E.L., Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab. Dispos. 32 (2004), 348–358.
113. [113] Kodama, S., Negishi, M., Sulfotransferase genes: regulation by nuclear receptors in response to xeno/endo-biotics. Drug Metab. Rev. 45 (2013), 441–449.
114. [114] Sugatani, J., Nishitani, S., Yamakawa, K., Yoshinari, K., Sueyoshi, T., Negishi, M., Miwa, M., Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol. 67 (2005), 845–855.
115. [115] Naik, A., Belic, A., Zanger, U.M., Rozman, D., Molecular interactions between NAFLD and xenobiotic metabolism. Front. Genet., 4, 2013, 2.
116. [116] Fisher, C.D., Lickteig, A.J., Augustine, L.M., Ranger-Moore, J., Jackson, J.P., Ferguson, S.S., Cherrington, N.J., Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Dispos. 37 (2009), 2087–2094.
117. [117] Hardwick, R.N., Fisher, C.D., Canet, M.J., Scheffer, G.L., Cherrington, N.J., Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39 (2011), 2395–2402.
118. [118] Ding, X., Lichti, K., Kim, I., Gonzalez, F.J., Staudinger, J.L., Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor α, and the coactivator peroxisome proliferator-activated receptor γ coactivator-1α. J. Biol. Chem. 281 (2006), 26540–26551.
119. [119] Kobayashi, K., Hashimoto, M., Honkakoski, P., Negishi, M., Regulation of gene expression by CAR: an update. Arch. Toxicol. 89 (2015), 1045–1055.
120. [120] Mutoh, S., Osabe, M., Inoue, K., Moore, R., Pedersen, L., Perera, L., Rebolloso, Y., Sueyoshi, T., Negishi, M., Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3). J. Biol. Chem. 284 (2009), 34785–34792.
121. [121] Kobayashi, K., Sueyoshi, T., Inoue, K., Moore, R., Negishi, M., Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol. Pharmacol. 64 (2003), 1069–1075.
122. [122] Honkakoski, P., Zelko, I., Sueyoshi, T., Negishi, M., The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol. Cell. Biol. 18 (1998), 5652–5658.
123. [123] Osabe, M., Negishi, M., Active ERK1/2 protein interacts with the phosphorylated nuclear constitutive active/androstane receptor (CAR; NR1I3), repressing dephosphorylation and sequestering CAR in the cytoplasm. J. Biol. Chem. 286 (2011), 35763–35769.
124. [124] Sidhu, J.S., Omiecinski, C.J., An okadaic acid-sensitive pathway involved in the phenobarbital-mediated induction of CYP2B gene expression in primary rat hepatocyte cultures. J. Pharmacol. Exp. Ther. 282 (1997), 1122–1129.
125. [125] Mutoh, S., Sobhany, M., Moore, R., Perera, L., Pedersen, L., Sueyoshi, T., Negishi, M., Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. Sci. Signal., 6, 2013, ra31.
126. [126] Ohno, M., Kanayama, T., Moore, R., Ray, M., Negishi, M., The roles of co-chaperone CCRP/DNAJC7 in Cyp2b10 gene activation and steatosis development in mouse livers. PLoS One, 9, 2014, e115663.
127. [127] Honkakoski, P., Moore, R., Washburn, K.A., Negishi, M., Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol. Pharmacol. 53 (1998), 597–601.
128. [128] Sueyoshi, T., Negishi, M., Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu. Rev. Pharmacol. Toxicol. 41 (2001), 123–143.
129. [129] Carazo, A., Pávek, P., The use of the LanthaScreen TR-FRET CAR coactivator assay in the characterization of constitutive androstane receptor (CAR) inverse agonists. Sensors 15 (2015), 9265–9276.
130. [130] Huang, W., Zhang, J., Chua, S.S., Qatanani, M., Han, Y., Granata, R., Moore, D.D., Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4156–4161.
131. [131] Saini, S.P., Sonoda, J., Xu, L., Toma, D., Uppal, H., Mu, Y., Ren, S., Moore, D.D., Evans, R.M., Xie, W., A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 65 (2004), 292–300.
132. [132] Shan, L., Vincent, J., Brunzelle, J.S., Dussault, I., Lin, M., Ianculescu, I., Sherman, M.A., Forman, B.M., Fernandez, E.J., Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. Mol. Cell 16 (2004), 907–917.
133. [133] Savary, C.C., Josse, R., Bruyere, A., Guillet, F., Robin, M.A., Guillouzo, A., Interactions of endosulfan and methoxychlor involving CYP3A4 and CYP2B6 in human HepaRG cells. Drug Metab. Dispos. 42 (2014), 1235–1240.
134. [134] Wyde, M.E., Bartolucci, E., Ueda, A., Zhang, H., Yan, B., Negishi, M., You, L., The environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor. Mol. Pharmacol. 64 (2003), 474–481.
135. [135] Zhang, X.J., Shi, Z., Lyv, J.X., He, X., Englert, N.A., Zhang, S.Y., Pyrene is a novel constitutive androstane receptor (CAR) activator and causes hepatotoxicity by CAR. Toxicol. Sci. 147 (2015), 436–445.
136. [136] Zhao, Y., Zhang, K., Giesy, J.P., Hu, J., Families of nuclear receptors in vertebrate models: characteristic and comparative toxicological perspective. Sci. Rep., 5, 2015, 8554.
137. [137] Dong, B., Saha, P.K., Huang, W., Chen, W., Abu-Elheiga, L.A., Wakil, S.J., Stevens, R.D., Ilkayeva, O., Newgard, C.B., Chan, L., Moore, D.D., Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 18831–18836.
138. [138] Gao, J., He, J., Zhai, Y., Wada, T., Xie, W., The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J. Biol. Chem. 284 (2009), 25984–25992.
139. [139] Kodama, S., Koike, C., Negishi, M., Yamamoto, Y., Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol. Cell. Biol. 24 (2004), 7931–7940.
140. [140] Gao, J., Yan, J., Xu, M., Ren, S., Xie, W., CAR suppresses hepatic gluconeogenesis by facilitating the ubiquitination and degradation of PGC1alpha. Mol. Endocrinol., 2015, me20151145.
141. [141] Sberna, A.L., Assem, M., Xiao, R., Ayers, S., Gautier, T., Guiu, B., Deckert, V., Chevriaux, A., Grober, J., Le Guern, N., Pais de Barros, J.P., Moore, D.D., Lagrost, L., Masson, D., Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 2232–2239.
142. [142] Roth, A., Looser, R., Kaufmann, M., Blattler, S.M., Rencurel, F., Huang, W., Moore, D.D., Meyer, U.A., Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol. Pharmacol. 73 (2008), 1282–1289.
143. [143] Masuyama, H., Hiramatsu, Y., Treatment with constitutive androstane receptor ligand during pregnancy prevents insulin resistance in offspring from high-fat diet-induced obese pregnant mice. Am. J. Physiol. Endocrinol. Metab. 303 (2012), E293–E300.
144. [144] Maglich, J.M., Lobe, D.C., Moore, J.T., The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J. Lipid Res. 50 (2009), 439–445.
145. [145] Baskin-Bey, E.S., Anan, A., Isomoto, H., Bronk, S.F., Gores, G.J., Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse. World J. Gastroenterol. 13 (2007), 5635–5641.
146. [146] Zordoky, B.N., El-Kadi, A.O., Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab. 10 (2009), 164–178.
147. [147] Zhou, C., Mutual Repression Between Steroid and Xenobiotic Receptor and NF-κB Signaling Pathways Links Xenobiotic Metabolism and Inflammation. 116, 2006, 2280–2289.
148. [148] Yamamoto, Y., Moore, R., Flavell, R.A., Lu, B., Negishi, M., Nuclear receptor CAR represses TNFalpha-induced cell death by interacting with the anti-apoptotic GADD45B. PLoS One, 5, 2010, e10121.
149. [149] Baskin-Bey, E.S., Huang, W., Ishimura, N., Isomoto, H., Bronk, S.F., Braley, K., Craig, R.W., Moore, D.D., Gores, G.J., Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology 44 (2006), 252–262.
150. [150] Yamazaki, Y., Kakizaki, S., Horiguchi, N., Sohara, N., Sato, K., Takagi, H., Mori, M., Negishi, M., The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 56 (2007), 565–574.
151. [151] Dong, B., Lee, J.S., Park, Y.Y., Yang, F., Xu, G., Huang, W., Finegold, M., Moore, D.D., Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat. Commun., 6, 2015, 5944.
152. [152] Li, D., Mackowiak, B., Brayman, T.G., Mitchell, M., Zhang, L., Huang, S.M., Wang, H., Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells. Biochem. Pharmacol. 98 (2015), 190–202.
153. [153] Luisier, R., Lempiainen, H., Scherbichler, N., Braeuning, A., Geissler, M., Dubost, V., Muller, A., Scheer, N., Chibout, S.D., Hara, H., Picard, F., Theil, D., Couttet, P., Vitobello, A., Grenet, O., Grasl-Kraupp, B., Ellinger-Ziegelbauer, H., Thomson, J.P., Meehan, R.R., Elcombe, C.R., Henderson, C.J., Wolf, C.R., Schwarz, M., Moulin, P., Terranova, R., Moggs, J.G., Phenobarbital induces cell cycle transcriptional responses in mouse liver humanized for constitutive androstane and pregnane x receptors. Toxicol. Sci. 139 (2014), 501–511.
154. [154] Russell, D.W., Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 1529 (2000), 126–135.
155. [155] Hong, C., Tontonoz, P., Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat. Rev. Drug Discov. 13 (2014), 433–444.
156. [156] Willy, P.J., Umesono, K., Ong, E.S., Evans, R.M., Heyman, R.A., Mangelsdorf, D.J., LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9 (1995), 1033–1045.
157. [157] Shinar, D.M., Endo, N., Rutledge, S.J., Vogel, R., Rodan, G.A., Schmidt, A., NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene 147 (1994), 273–276.
158. [158] Ahn, S.B., Jang, K., Jun, D.W., Lee, B.H., Shin, K.J., Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig. Dis. Sci. 59 (2014), 2975–2982.
159. [159] Ito, A., Hong, C., Rong, X., Zhu, X., Tarling, E.J., Hedde, P.N., Gratton, E., Parks, J., Tontonoz, P., LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. Elife, 4, 2015, e08009.
160. [160] Hu, X., Li, S., Wu, J., Xia, C., Lala, D.S., Liver X receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 17 (2003), 1019–1026.
161. [161] Quack, M., Frank, C., Carlberg, C., Differential nuclear receptor signalling from DR4-type response elements. J. Cell. Biochem. 86 (2002), 601–612.
162. [162] Frank, C., Gonzalez, M.M., Oinonen, C., Dunlop, T.W., Carlberg, C., Characterization of DNA complexes formed by the nuclear receptor constitutive androstane receptor. J. Biol. Chem. 278 (2003), 43299–43310.
163. [163] Frank, C., Makkonen, H., Dunlop, T.W., Matilainen, M., Vaisanen, S., Carlberg, C., Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J. Mol. Biol. 346 (2005), 505–519.
164. [164] Gill, S., Chow, R., Brown, A.J., Sterol regulators of cholesterol homeostasis and beyond: the oxysterol hypothesis revisited and revised. Prog. Lipid Res. 47 (2008), 391–404.
165. [165] Shenoy, S.D., Spencer, T.A., Mercer-Haines, N.A., Alipour, M., Gargano, M.D., Runge-Morris, M., Kocarek, T.A., CYP3A induction by liver X receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor. Drug Metab. Dispos. 32 (2004), 66–71.
166. [166] Mitro, N., Vargas, L., Romeo, R., Koder, A., Saez, E., T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 581 (2007), 1721–1726.
167. [167] Mozzicafreddo, M., Cuccioloni, M., Bonfili, L., Cecarini, V., Palermo, F.A., Cocci, P., Mosconi, G., Capone, A., Ricci, I., Eleuteri, A.M., Angeletti, M., Environmental pollutants directly affect the liver X receptor alpha activity: kinetic and thermodynamic characterization of binding. J. Steroid Biochem. Mol. Biol. 152 (2015), 1–7.
168. [168] Gerin, I., Dolinsky, V.W., Shackman, J.G., Kennedy, R.T., Chiang, S.H., Burant, C.F., Steffensen, K.R., Gustafsson, J.A., MacDougald, O.A., LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J. Biol. Chem. 280 (2005), 23024–23031.
169. [169] Fernandez-Alvarez, A., Alvarez, M.S., Gonzalez, R., Cucarella, C., Muntane, J., Casado, M., Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 286 (2011), 21466–21477.
170. [170] Matsukuma, K.E., Bennett, M.K., Huang, J., Wang, L., Gil, G., Osborne, T.F., Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase. J. Lipid Res. 47 (2006), 2754–2761.
171. [171] Zhang, Y., Breevoort, S.R., Angdisen, J., Fu, M., Schmidt, D.R., Holmstrom, S.R., Kliewer, S.A., Mangelsdorf, D.J., Schulman, I.G., Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J. Clin. Invest. 122 (2012), 1688–1699.
172. [172] Archer, A., Venteclef, N., Mode, A., Pedrelli, M., Gabbi, C., Clement, K., Parini, P., Gustafsson, J.A., Korach-Andre, M., Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice. Mol. Endocrinol. 26 (2012), 1980–1990.
173. [173] Costet, P., Luo, Y., Wang, N., Tall, A.R., Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275 (2000), 28240–28245.
174. [174] Kennedy, M.A., Venkateswaran, A., Tarr, P.T., Xenarios, I., Kudoh, J., Shimizu, N., Edwards, P.A., Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276 (2001), 39438–39447.
175. [175] Menke, J.G., Macnaul, K.L., Hayes, N.S., Baffic, J., Chao, Y.S., Elbrecht, A., Kelly, L.J., Lam, M.H., Schmidt, A., Sahoo, S., Wang, J., Wright, S.D., Xin, P., Zhou, G., Moller, D.E., Sparrow, C.P., A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology 143 (2002), 2548–2558.
176. [176] Wong, J., Quinn, C.M., Gelissen, I.C., Brown, A.J., Endogenous 24(S),25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J.Biol. Chem. 283 (2008), 700–707.
177. [177] Ding, L., Pang, S., Sun, Y., Tian, Y., Yu, L., Dang, N., Coordinated actions of FXR and LXR in metabolism: from pathogenesis to pharmacological targets for type 2 diabetes. Int. J. Endocrinol., 2014, 2014, 751859.
178. [178] Venteclef, N., Jakobsson, T., Ehrlund, A., Damdimopoulos, A., Mikkonen, L., Ellis, E., Nilsson, L.M., Parini, P., Janne, O.A., Gustafsson, J.A., Steffensen, K.R., Treuter, E., GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev. 24 (2010), 381–395.
179. [179] Zhu, X., Owen, J.S., Wilson, M.D., Li, H., Griffiths, G.L., Thomas, M.J., Hiltbold, E.M., Fessler, M.B., Parks, J.S., Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 51 (2010), 3196–3206.
180. [180] Rahman, S.M., Choudhury, M., Janssen, R.C., Baquero, K.C., Miyazaki, M., Friedman, J.E., CCAAT/enhancer binding protein beta deletion increases mitochondrial function and protects mice from LXR-induced hepatic steatosis. Biochem. Biophys. Res. Commun. 430 (2013), 336–339.
181. [181] Griffett, K., Solt, L.A., El-Gendy Bel, D., Kamenecka, T.M., Burris, T.P., A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem. Biol. 8 (2013), 559–567.
182. [182] Griffett, K., Welch, R.D., Flaveny, C.A., Kolar, G.R., Neuschwander-Tetri, B.A., Burris, T.P., The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol. Metab. 4 (2015), 353–357.
183. [183] Shah, I., Houck, K., Judson, R.S., Kavlock, R.J., Martin, M.T., Reif, D.M., Wambaugh, J., Dix, D.J., Using nuclear receptor activity to stratify hepatocarcinogens. PLoS One, 6, 2011, e14584.
184. [184] Boesjes, M., Bloks, V.W., Hageman, J., Bos, T., van Dijk, T.H., Havinga, R., Wolters, H., Jonker, J.W., Kuipers, F., Groen, A.K., Hepatic farnesoid X-receptor isoforms alpha2 and alpha4 differentially modulate bile salt and lipoprotein metabolism in mice. PLoS One, 9, 2014, e115028.
185. [185] Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., Staels, B., Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89 (2009), 147–191.
186. [186] Yang, Z.X., Shen, W., Sun, H., Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol. Int. 4 (2010), 741–748.
187. [187] Matsubara, T., Li, F., Gonzalez, F.J., FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol. 368 (2013), 17–29.
188. [188] Hsu, C.W., Zhao, J., Huang, R., Hsieh, J.H., Hamm, J., Chang, X., Houck, K., Xia, M., Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci. Rep., 4, 2014, 6437.
189. [189] de Aguiar Vallim, T.Q., Tarling, E.J., Edwards, P.A., Pleiotropic roles of bile acids in metabolism. Cell Metab. 17 (2013), 657–669.
190. [190] Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., Luo, G., Jones, S.A., Goodwin, B., Richardson, J.A., Gerard, R.D., Repa, J.J., Mangelsdorf, D.J., Kliewer, S.A., Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2 (2005), 217–225.
191. [191] Jones, S.A., Physiology of FGF15/19. Adv. Exp. Med. Biol. 728 (2012), 171–182.
192. [192] Xie, M.H., Holcomb, I., Deuel, B., Dowd, P., Huang, A., Vagts, A., Foster, J., Liang, J., Brush, J., Gu, Q., Hillan, K., Goddard, A., Gurney, A.L., FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11 (1999), 729–735.
193. [193] Cyphert, H.A., Ge, X., Kohan, A.B., Salati, L.M., Zhang, Y., Hillgartner, F.B., Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J. Biol. Chem. 287 (2012), 25123–25138.
194. [194] Lin, Z., Tian, H., Lam, K.S., Lin, S., Hoo, R.C., Konishi, M., Itoh, N., Wang, Y., Bornstein, S.R., Xu, A., Li, X., Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17 (2013), 779–789.
195. [195] Kunne, C., Acco, A., Duijst, S., de Waart, D.R., Paulusma, C.C., Gaemers, I., Oude Elferink, R.P.J., FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model. Biochim. Biophys. Acta 1842 (2014), 739–746.
196. [196] Shen, L.-L., Liu, H., Peng, J., Gan, L., Lu, L., Zhang, Q., Li, L., He, F., Jiang, Y., Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase. Mol. Biol. Rep. 38 (2011), 553–559.
197. [197] Pineda Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J.-C., Staels, B., Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17 (2003), 259–272.
198. [198] Watanabe, M., Houten, S.M., Wang, L., Moschetta, A., Mangelsdorf, D.J., Heyman, R.A., Moore, D.D., Auwerx, J., Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113 (2004), 1408–1418.
199. [199] Cipriani, S., Mencarelli, A., Palladino, G., Fiorucci, S., FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51 (2010), 771–784.
200. [200] Ma, Y., Huang, Y., Yan, L., Gao, M., Liu, D., Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm. Res. 30 (2013), 1447–1457.
201. [201] Evans, M.J., Mahaney, P.E., Borges-Marcucci, L., Lai, K., Wang, S., Krueger, J.A., Gardell, S.J., Huard, C., Martinez, R., Vlasuk, G.P., Harnish, D.C., A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009), G543–G552.
202. [202] Claudel, T., Sturm, E., Duez, H., Torra, I.P., Sirvent, A., Kosykh, V., Fruchart, J.-C., Dallongeville, J., Hum, D.W., Kuipers, F., Staels, B., Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109 (2002), 961–971.
203. [203] Urizar, N.L., Liverman, A.B., Dodds, D.N.T., Silva, F.V., Ordentlich, P., Yan, Y., Gonzalez, F.J., Heyman, R.A., Mangelsdorf, D.J., Moore, D.D., A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296 (2002), 1703–1706.
204. [204] Huang, H., Yu, Y., Gao, Z., Zhang, Y., Li, C., Xu, X., Jin, H., Yan, W., Ma, R., Zhu, J., Shen, X., Jiang, H., Chen, L., Li, J., Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists. J. Med. Chem. 55 (2012), 7037–7053.
205. [205] Xu, X., Xu, X., Liu, P., Zhu, Z.-Y., Chen, J., Fu, H.-A., Chen, L.-L., Hu, L.-H., Shen, X., Structural basis for small molecule NDB (N-benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide) as a selective antagonist of farnesoid X receptor alpha (FXRalpha) in stabilizing the homodimerization of the receptor. J. Biol. Chem. 290 (2015), 19888–19899.
206. [206] Mudaliar, S., Henry, R.R., Sanyal, A.J., Morrow, L., Marschall, H.U., Kipnes, M., Adorini, L., Sciacca, C.I., Clopton, P., Castelloe, E., Dillon, P., Pruzanski, M., Shapiro, D., Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 574–582 e571.
207. [207] Watanabe, M., Horai, Y., Houten, S.M., Morimoto, K., Sugizaki, T., Arita, E., Mataki, C., Sato, H., Tanigawara, Y., Schoonjans, K., Itoh, H., Auwerx, J., Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 286 (2011), 26913–26920.
208. [208] Zhang, Y., Lee, F.Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F.J., Willson, T.M., Edwards, P.A., Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 1006–1011.
209. [209] Stayrook, K.R., Bramlett, K.S., Savkur, R.S., Ficorilli, J., Cook, T., Christe, M.E., Michael, L.F., Burris, T.P., Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146 (2005), 984–991.
210. [210] Yamagata, K., Daitoku, H., Shimamoto, Y., Matsuzaki, H., Hirota, K., Ishida, J., Fukamizu, A., Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 279 (2004), 23158–23165.
211. [211] Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J.P., Tsai, S.P., Powell-Braxton, L., French, D., Stewart, T.A., Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143 (2002), 1741–1747.
212. [212] Fu, L., John, L.M., Adams, S.H., Yu, X.X., Tomlinson, E., Renz, M., Williams, P.M., Soriano, R., Corpuz, R., Moffat, B., Vandlen, R., Simmons, L., Foster, J., Stephan, J.-P., Tsai, S.P., Stewart, T.A., Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145 (2004), 2594–2603.
213. [213] Fang, S., Suh, J.M., Reilly, S.M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., Atkins, A.R., Khvat, A., Schnabl, B., Yu, R.T., Brenner, D.A., Coulter, S., Liddle, C., Schoonjans, K., Olefsky, J.M., Saltiel, A.R., Downes, M., Evans, R.M., Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21 (2015), 159–165.
214. [214] Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R.T., Shelton, J.M., Richardson, J.A., Repa, J.J., Mangelsdorf, D.J., Kliewer, S.A., Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 3920–3925.
215. [215] Li, F., Jiang, C., Krausz, K.W., Li, Y., Albert, I., Hao, H., Fabre, K.M., Mitchell, J.B., Patterson, A.D., Gonzalez, F.J., Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun., 4, 2013, 2384.
216. [216] Jonker, J.W., Liddle, C., Downes, M., FXR and PXR: potential therapeutic targets in cholestasis. J. Steroid Biochem. Mol. Biol. 130 (2012), 147–158.
217. [217] Ferslew, B.C., Xie, G., Johnston, C.K., Su, M., Stewart, P.W., Jia, W., Brouwer, K.L., Barritt, A.t. Sidney, Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig. Dis. Sci. 60 (2015), 3318–3328.
218. [218] Inagaki, T., Moschetta, A., Lee, Y.K., Peng, L., Zhao, G., Downes, M., Yu, R.T., Shelton, J.M., Richardson, J.A., Repa, J.J., Mangelsdorf, D.J., Kliewer, S.A., Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 3920–3925.
219. [219] Kong, B., Luyendyk, J.P., Tawfik, O., Guo, G.L., Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 328 (2009), 116–122.
220. [220] Zhang, S., Wang, J., Liu, Q., Harnish, D.C., Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51 (2009), 380–388.
221. [221] Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D.D., Huang, W., Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67 (2007), 863–867.
222. [222] Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J.M., Gonzalez, F.J., Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28 (2007), 940–946.
223. [223] Wolfe, A., Thomas, A., Edwards, G., Jaseja, R., Guo, G.L., Apte, U., Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J. Pharmacol. Exp. Ther. 338 (2011), 12–21.
224. [224] Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., Kannisto, K., Parini, P., Moschetta, A., Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology 61 (2015), 161–170.
225. [225] Kassam, A., Winrow, C.J., Fernandez-Rachubinski, F., Capone, J.P., Rachubinski, R.A., The peroxisome proliferator response element of the gene encoding the peroxisomal beta-oxidation enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase is a target for constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated transactivation. J. Biol. Chem. 275 (2000), 4345–4350.
226. [226] Zhai, Y., Wada, T., Zhang, B., Khadem, S., Ren, S., Kuruba, R., Li, S., Xie, W., A functional cross-talk between liver X receptor-alpha and constitutive androstane receptor links lipogenesis and xenobiotic responses. Mol. Pharmacol. 78 (2010), 666–674.
227. [227] Nan, Y.M., Kong, L.B., Ren, W.G., Wang, R.Q., Du, J.H., Li, W.C., Zhao, S.X., Zhang, Y.G., Wu, W.J., Di, H.L., Li, Y., Yu, J., Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice. Lipids Health Dis., 12, 2013, 11.
228. [228] Je, Y.T., Sim, W.C., Kim, D.G., Jung, B.H., Shin, H.S., Lee, B.H., Expression of CYP3A in chronic ethanol-fed mice is mediated by endogenous pregnane X receptor ligands formed by enhanced cholesterol metabolism. Arch. Toxicol. 89 (2015), 579–589.
229. [229] Chen, X., Meng, Z., Wang, X., Zeng, S., Huang, W., The nuclear receptor CAR modulates alcohol-induced liver injury. Lab. Investig. 91 (2011), 1136–1145.
230. [230] Na, T.Y., Han, Y.H., Ka, N.L., Park, H.S., Kang, Y.P., Kwon, S.W., Lee, B.H., Lee, M.O., 22-S-hydroxycholesterol protects against ethanol-induced liver injury by blocking the auto/paracrine activation of MCP-1 mediated by LXRalpha. J. Pathol. 235 (2015), 710–720.
231. [231] Manley, S., Ding, W., Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm. Sin. B 5 (2015), 158–167.
232. [232] Ferno, J., Vik-Mo, A.O., Jassim, G., Havik, B., Berge, K., Skrede, S., Gudbrandsen, O.A., Waage, J., Lunder, N., Mork, S., Berge, R.K., Jorgensen, H.A., Steen, V.M., Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 203 (2009), 73–84.
233. [233] Wahlang, B., Prough, R.A., Falkner, K.C., Hardesty, J.E., Song, M., Clair, H.B., Clark, B.J., States, J.C., Arteel, G.E., Cave, M.C., Polychlorinated biphenyl-xenobiotic nuclear receptor interactions regulate energy metabolism, behavior, and inflammation in nonalcoholic-steatohepatitis. Toxicol. Sci. 149 (2016), 396–410.
234. [234] Maranghi, F., Lorenzetti, S., Tassinari, R., Moracci, G., Tassinari, V., Marcoccia, D., Di Virgilio, A., Eusepi, A., Romeo, A., Magrelli, A., Salvatore, M., Tosto, F., Viganotti, M., Antoccia, A., Di Masi, A., Azzalin, G., Tanzarella, C., Macino, G., Taruscio, D., Mantovani, A., In utero exposure to di-(2-ethylhexyl) phthalate affects liver morphology and metabolism in post-natal CD-1 mice. Reprod. Toxicol. 29 (2010), 427–432.
235. [235] Wei, J., Sun, X., Chen, Y., Li, Y., Song, L., Zhou, Z., Xu, B., Lin, Y., Xu, S., Perinatal exposure to bisphenol A exacerbates nonalcoholic steatohepatitis-like phenotype in male rat offspring fed on a high-fat diet. J Endocrinol 222 (2014), 313–325.
236. [236] Tan, X., Xie, G., Sun, X., Li, Q., Zhong, W., Qiao, P., Sun, X., Jia, W., Zhou, Z., High fat diet feeding exaggerates perfluorooctanoic acid-induced liver injury in mice via modulating multiple metabolic pathways. PLoS One, 8, 2013, e61409.
237. [237] Attia, A.M., El-Banna, S.G., Nomeir, F.R., Abd El-Basser, M.I., Lindane-induced biochemical perturbations in rat serum and attenuation by omega-3 and Nigella sativa seed oil. Indian J. Biochem. Biophys. 48 (2011), 184–190.
238. [238] Mehta, R., Birerdinc, A., Younossi, Z.M., Host genetic variants in obesity-related nonalcoholic fatty liver disease. Clin. Liver. Dis. 18 (2014), 249–267.
239. [239] Pawlak, M., Lefebvre, P., Staels, B., Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62 (2015), 720–733.
240. [240] Webb, S.J., Geoghegan, T.E., Prough, R.A., Michael Miller, K.K., The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab. Rev. 38 (2006), 89–116.
241. [241] Kersten, S., Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res., 2008, 2008, 132960.
242. [242] Azuma, Y.T., Nishiyama, K., Matsuo, Y., Kuwamura, M., Morioka, A., Nakajima, H., Takeuchi, T., PPARalpha contributes to colonic protection in mice with DSS-induced colitis. Int. Immunopharmacol. 10 (2010), 1261–1267.
243. [243] Kostadinova, R., Montagner, A., Gouranton, E., Fleury, S., Guillou, H., Dombrowicz, D., Desreumaux, P., Wahli, W., GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell Biosci, 2, 2012, 34.
244. [244] Hollingshead, H.E., Morimura, K., Adachi, M., Kennett, M.J., Billin, A.N., Willson, T.M., Gonzalez, F.J., Peters, J.M., PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig. Dis. Sci. 52 (2007), 2912–2919.
245. [245] Lee, J.W., Bajwa, P.J., Carson, M.J., Jeske, D.R., Cong, Y., Elson, C.O., Lytle, C., Straus, D.S., Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology 133 (2007), 108–123.
246. [246] Enomoto, N., Takei, Y., Hirose, M., Konno, A., Shibuya, T., Matsuyama, S., Suzuki, S., Kitamura, K.I., Sato, N., Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J. Pharmacol. Exp. Ther. 306 (2003), 846–854.
247. [247] Greger, D.L., Gropp, F., Morel, C., Sauter, S., Blum, J.W., Nuclear receptor and target gene mRNA abundance in duodenum and colon of dogs with chronic enteropathies. Domest. Anim. Endocrinol. 31 (2006), 327–339.
248. [248] Repa, J.J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.M., Shimomura, I., Shan, B., Brown, M.S., Goldstein, J.L., Mangelsdorf, D.J., Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14 (2000), 2819–2830.
249. [249] Andersen, V., Christensen, J., Ernst, A., Jacobsen, B.A., Tjonneland, A., Krarup, H.B., Vogel, U., Polymorphisms in NF-kappaB, PXR, LXR, PPARgamma and risk of inflammatory bowel disease. World J. Gastroenterol. 17 (2011), 197–206.
250. [250] Heimerl, S., Moehle, C., Zahn, A., Boettcher, A., Stremmel, W., Langmann, T., Schmitz, G., Alterations in intestinal fatty acid metabolism in inflammatory bowel disease. Biochim. Biophys. Acta 1762 (2006), 341–350.
251. [251] Hernandez, J.P., Mota, L.C., Baldwin, W.S., Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation. Curr. Pharm. Pers. Med. 7 (2009), 81–105.